Human Epilepsy Project 2: Resistant Focal Seizures Study



Status:Recruiting
Conditions:Neurology, Epilepsy
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:16 - 65
Updated:6/10/2018
Start Date:May 7, 2018
End Date:September 2020
Contact:Brandy Fureman, PhD
Email:BFureman@efa.org
Phone:1-800-332-1000

Use our guide to learn which trials are right for you!

Biomarkers, Health Outcomes and Healthcare Utilization in People With Resistant Focal Epilepsy

The HEP2 study is designed to better understand the challenges of living with focal seizures
that do not respond to medication, by following 205 people with medication-resistant focal
epilepsy over two years to measure changes in health status, healthcare costs, quality of
life, and biomarkers of epilepsy severity and treatment response.

The Epilepsy Foundation is launching a partnership, called the Human Epilepsy Project, in
collaboration with the Epilepsy Study Consortium. This study (which is called HEP2 for short)
is designed to better understand the challenges of living with focal seizures that do not
respond to medication. The HEP2 study will follow 200 people with medication-resistant focal
epilepsy (with seizures that occur at least 4 times per month) over two years to measure
changes in their seizure frequency, treatments used, adverse events experienced, presence of
co-morbidities like depression and anxiety, healthcare costs, and quality of life. Blood
samples will also be collected in order to look for biomarkers of epilepsy severity and
treatment response.

Participants can join the HEP2 study at any one of nine recruiting study centers. These study
centers were selected because they are epilepsy centers with track records of conducting
high-quality research in epilepsy and efficiently recruiting participants into studies. The
designated sites for the HEP2 study are located in New York, California, Minnesota,
Connecticut, Pennsylvania, and Tennessee. The study has one international site in Finland. A
participant may enroll in the HEP2 study but continue to receive their standard epilepsy care
with their current physician, as long as the participant is willing to share his or her
medical records, and travel to the study center for three in person visits at the beginning
of the study, after the first year, and a final visit after the second year.

Inclusion Criteria:

1. Age ≥ 16 years and ≤ 65 years at time of enrollment

2. Diagnosed with focal epilepsy with prior vEEG confirmation; if no VEEG confirmation,
but in the opinion of the investigator the seizures are definite, the case can be
reviewed and adjudicated by the consortium

3. Failure of adequate trials of 4 AEDs, with at least 2 due to failure of seizure
control, including current AEDs

4. Have a seizure frequency of ≥ 4 focal seizures/month, including auras, and at least 2
observable seizures/month, that are countable by the subject and/or caregiver for the
3 months prior to enrollment

5. Able to keep a daily seizure diary, either independently or with assistance from a
caregiver

6. Able to retrospectively report number of seizures/month for 3 months prior to
enrollment

7. Receiving ≥ 1 AED for treatment of seizures

Exclusion Criteria:

1. Patient has a diagnosis of idiopathic ("primary") generalized epilepsy (e.g., juvenile
myoclonic epilepsy, absence epilepsy) or mixed focal and generalized (e.g.,
Lennox-Gastaut syndrome) or non-epileptic seizures within the last 12 months prior to
study entry

2. Progressive medical or neurological disorder (brain tumor, AD, PME, etc.)

3. Proven autoimmune etiology

4. Planning pregnancy in the next 12 months

5. Intent to pursue surgical resection intervention in the next two years

6. Resective surgery and/or RNS/VNS in place less than 12 months prior to enrollment

7. Presence of moderate or greater developmental or cognitive delay (e.g., if an
adolescent, not in self-contained classroom; if IQ is documented, should be ≥ 70)

8. History of chronic drug or alcohol abuse (misuse or excessive use that interferes with
activities of daily living) within the last 2 years

9. Medical, psychiatric or psychosocial condition that would be expected to interfere
with the conduct of the study
We found this trial at
9
sites
3400 Spruce St
Philadelphia, Pennsylvania 19104
 (215) 662-4000
Principal Investigator: Michael Gelfand, MD, PhD
Phone: 215-662-7227
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Kuopio,
Principal Investigator: Reetta Kalviainen
?
mi
from
Kuopio,
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Bassel Abou-Khalil, MD
Phone: 615-322-8817
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Haven, Connecticut 06520
Principal Investigator: Kamil Detyniecki, MD
Phone: 203-785-3638
?
mi
from
New Haven, CT
Click here to add this to my saved trials
70 Washington Square S
New York, New York 10012
(212) 998-1212
Principal Investigator: Manisha Holmes, MD
Phone: 646-558-0810
New York University More than 175 years ago, Albert Gallatin, the distinguished statesman who served...
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10075
Principal Investigator: Ruben Kuzniecky, MD
?
mi
from
New York, NY
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Gregory Cascino, MD
Phone: 507-284-0451
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Paul, Minnesota
Principal Investigator: Paul Atkinson, MD
Phone: 651-241-5304
?
mi
from
Saint Paul, MN
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Manu Hegde, MD, PhD
Phone: 415-353-3738
?
mi
from
San Francisco, CA
Click here to add this to my saved trials